Stay updated on Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The record for the completed margetuximab–pembrolizumab study is available, with details about its design, participants, sites, and results measures, along with study documents and publications.
    Difference
    67%
    Check dated 2026-11-08T13:18:26.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-01T13:58:11.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T13:25:48.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:28:01.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T13:57:58.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record details, indicating the record is currently inaccessible.
    Difference
    19%
    Check dated 2026-09-20T20:41:59.000Z thumbnail image

Stay in the know with updates to Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.